BRAF and cancer: Although BRAF-selective inhibitors block ERK signaling in tumors with BRAF mutation, they paradoxically activate ERK signaling and accelerate the growth of tumors with wild-type (WT) BRAF or with RAS mutations [10–12], thereby limiting the usefulness of BRAF inhibitors as a cancer therapy.